Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has announced a proposed underwritten public offering of common stock or pre-funded warrants in lieu of common stock, together with accompanying warrants to purchase common stock. The securities will be issued separately but must be purchased together, with Canaccord Genuity acting as sole bookrunner. The company intends to use the net proceeds to advance clinical development of its investigational oral therapy buntanetap for Alzheimer's disease and Parkinson's disease, as well as for working capital and general corporate purposes.
The announcement is significant because it highlights the financial strategy of a clinical-stage biotech firm racing to bring a potential disease-modifying treatment to market. Buntanetap is designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. With no approved therapies that stop or slow these diseases, successful development could address a massive unmet need.
However, the offering remains subject to market and other conditions, and there is no assurance regarding its completion, size, or terms. For investors, the move signals both opportunity and risk: the capital raise could extend the company's runway and accelerate trials, but dilution and financing uncertainty are inherent. The proceeds are earmarked specifically for buntanetap's clinical advancement, underscoring the drug's importance to Annovis's future. For a full details, see the full press release.
Annovis Bio, headquartered in Malvern, Pennsylvania, is developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides editorial syndication to 5,000+ outlets and other services. For full terms, see the disclaimer.


